about
Structure of the yeast ribonucleotide reductase Y2Y4 heterodimerSafety of hydroxyurea in the treatment of HIV infection.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition.Mechanism-based inhibition of ribonucleotide reductases: new mechanistic considerations and promising biological applications.Nucleotide metabolism, oncogene-induced senescence and cancer.Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.Developing treatment for sickle cell disease.Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.Massive accidental overdose of hydroxyurea in a young child with sickle cell anemiaRibonucleotide reductase inhibitors: a new look at an old target for radiosensitization.Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomasDevelopment of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine.Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.Drugs in development for toxoplasmosis: advances, challenges, and current status.ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin inductionHydroxyurea induced acute elevations in liver function tests.Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy.Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.Anti-parasitic action and elimination of intracellular Toxoplasma gondii in the presence of novel thiosemicarbazone and its 4-thiazolidinone derivatives.Effect of hydroxyurea on the intracellular multiplication of Toxoplasma gondii, Leishmania amazonensis and Trypanosoma cruzi.Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.Leukemoid Reaction in Infant Pertussis: Is There a Place for Hydroxyurea? A Case Report
P2860
Q27634566-2F98A1AF-9328-46C0-B52E-52E697F9F9D3Q30946270-71B6B323-C7BC-4B7B-8F28-E96D3E03ECEEQ33419794-EDD7FE99-CC79-4644-9558-D893C0712D73Q33699869-0D324BAB-1C5C-44F8-9181-101BDA6A6963Q33702981-34257C04-F459-4F70-9371-4FDDEFB8A6EEQ33969333-7BE7351B-889B-471F-9ED2-0D1C0AE755B2Q34171747-4FEE287A-C0E4-45F8-BBA6-D1D88320A4F4Q34185007-430CA80A-B4CE-4033-8A0E-556B67D26E1EQ34628666-98B91569-9DE7-4860-B171-D9BEB1FED0E4Q35053910-CAF07402-784B-4AC0-B24B-29FA6D3546D7Q35353627-02ED713C-D0BB-495F-82E2-6E583B2110D2Q35971759-CD6A8499-AB96-404A-944A-3DB753214669Q36533485-86578171-040F-4B0A-81AE-98EA039041DBQ36549467-BE935046-0660-458D-B570-84F66C6EA384Q36706798-44AB81B1-E190-4D61-989E-2FA2798204E6Q36926046-6170D72B-4543-4544-BFB8-2EC4646D6EFFQ37439697-7B5401E0-F6A4-4498-88EB-3147A51F717EQ37613765-01CC384C-63B7-466D-B87A-5A623B6D475BQ37618816-AB547AAF-AAD9-45A1-9A53-899515A638FEQ38253004-16FBBD35-4882-4F53-8892-FB5DD8B456EAQ39741020-77F825CF-3039-48C1-9054-50934B4EFE1DQ40424719-18BB663C-B93D-4FF4-8B90-A4B5D2AACD22Q40720173-2CE86C3C-ED94-49BF-AFFE-291D12606478Q42878312-4F1F87E6-E622-4F60-96FF-10576ED4386AQ43247377-1E97155E-D821-4BB2-B932-BBD3E52802F5Q44281099-5B413F4E-C051-46D9-A2C0-8CD17D0CF4A0Q44582907-0A156D64-26A5-401D-8F25-52CB68C9F733Q46063040-A2876D0F-CBB8-4688-B604-F6CE16822051Q46391225-31C689B8-3530-4490-931B-B2DAC54902AFQ46906655-8DA659B8-DC7A-45E8-82B3-485BB2CD582BQ46922191-311AD443-43F6-405B-B222-E84E6DCBEE7BQ48015152-B1A581E0-E6DA-4ED8-B4FD-2A4CB8740F71Q52620954-46787CDD-A19C-4874-BE36-DA74217928B1Q57821277-1B64EE69-13EA-401E-B0E4-D7E45F28E57D
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@ast
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@en
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@nl
type
label
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@ast
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@en
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@ast
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@en
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@nl
P1476
Pharmacokinetics and pharmacodynamics of hydroxyurea.
@en
P2093
Tracewell WG
P304
P356
10.2165/00003088-199834050-00002
P577
1998-05-01T00:00:00Z
P6179
1002543845